Combined Intrathecal Dexmedetomidine and Adductor Canal Block for Analgesia After Total Knee Arthroplasty

Sponsor
Kafrelsheikh University
Study ID
NCT06837844
Status
Recruiting
Apply to this trial

Conditions

  • Adductor Canal Block
  • Analgesia
  • Intrathecal Dexmedetomidine
  • Total Knee Arthroplasty

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Intrathecal Dexmedetomidine — DRUG
    Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml saline 0.9% at the end of surgery
  • Adductor Canal Block — DRUG
    Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 0.5ml saline 0.9% + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
  • Intrathecal Dexmedetomidine + Adductor Canal Block — DRUG
    Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.

Study Details

The aim of this work is to evaluate the effect of combined intrathecal dexmedetomidine and adductor canal block for analgesia after total knee arthroplasty (TKA).

Key Dates

First listed
Feb 20, 2025
Start date
Feb 20, 2025
Status verified
Feb 2025
Primary completion
Aug 1, 2025
Completion
Aug 1, 2025

Study Design

Enrollment
75 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Group ITD
    Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml saline 0.9% at the end of surgery
  • Active Comparator: Group ACB
    Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 0.5ml saline 0.9% + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.
  • Experimental: Group ITD+ACB
    Patients will receive 15mg in 3ml hyperbaric bupivacaine intrathecally with 5 μg in 0.5ml dexmedetomidine + adductor canal block using 20 ml bupivacaine 0.25% at the end of surgery.

Primary Outcome Measure

Total morphine consumption [ Time Frame: 48 hours postoperatively ]

Central Contacts

Related Studies